Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 12/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14785737 | 0.87 | KCNJ1 (0.72) | KCNJ1KCNH2HRH3SIGMAR1HTR2A | |
| SCHEMBL5151630 | 0.86 | KCNJ1 (0.70) | KCNJ1KCNH2HRH3SIGMAR1HTR2A | |
| SCHEMBL2731306 | 0.83 | KCNJ1 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL9235484 | 0.83 | KCNJ1 (0.74) | KCNJ1KCNH2HRH3SIGMAR1HTR2A | |
| SCHEMBL27178650 | 0.81 | SIRT6 (0.55) | HTR2A | |
| SCHEMBL3156895 | 0.81 | HRH3 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL5653299 | 0.81 | HRH3 (0.93) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL14786379 | 0.80 | HTR2A (0.72) | KCNJ1KCNH2HRH3SIGMAR1HTR2A | |
| SCHEMBL914324 | 0.79 | HRH3 (0.97) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL3156570 | 0.79 | HRH3 (0.97) | KCNJ1KCNH2HRH3SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700551-B2 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-07-11 | — | — | US | disclosed |
| US-20160045485-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) | 2016-02-18 | — | — | US | disclosed |
| EP-2817301-B1 | USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | ACRAF (IT) | 2015-12-23 | — | — | EP | disclosed |
| US-9163013-B2 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-10-20 | — | — | US | disclosed |
| EP-2817301-A1 | USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2014-12-31 | — | — | EP | disclosed |
| US-20140378455-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-12-25 | — | — | US | disclosed |
| WO-2013124169-A1 | USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-29 | — | — | WO | disclosed |
| US-8415476-B2 | Indazole having analgesic activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-04-09 | — | — | US | disclosed |
| EP-1622892-B1 | INDAZOLES HAVING ANALGESIC ACTIVITY | ACRAF (IT) | 2011-03-09 | — | — | EP | disclosed |
| US-20100094015-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY | AZIENDE CHIM. RIUN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-7662836-B2 | Indazole having analgesic activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-02-16 | — | — | US | disclosed |
| US-20070010555-A1 | Indazole having analgesic activity | AZIENDE CHIM. RUIN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094015-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY | OPRK1, OPRD1, ACHE | KCNJ1 759/4885KCNH2 616/4885HRH3 360/4885 |
| US-20140378455-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3B, GSK3A, PYGB | KCNJ1 1921/4885KCNH2 2047/4885HRH3 4071/4885 |
| US-20160045485-A1 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3A, GSK3B, PYGB | KCNJ1 2008/4885KCNH2 1768/4885HRH3 3502/4885 |
| US-20070010555-A1 | Indazole having analgesic activity | ACHE, CYP3A43, RPL35A | KCNJ1 673/4885KCNH2 583/4885HRH3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.